Navigation Links
Biotechnology Value Fund, L.P. To Make Tender Offer For Any And All Outstanding Shares Of Avigen At $1.00 Per Share
Date:1/15/2009

e they will contain important information.

Questions should be directed to the information agent, MacKenzie Partners, Inc., at (800) 322-2885.

THIS PRESS RELEASE IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT AN OFFER TO BUY OR THE SOLICITATION OF AN OFFER TO SELL ANY SHARES. BVF HAS NOT YET COMMENCED THE OFFER REFERRED TO IN THIS PRESS RELEASE. THE SOLICITATION AND THE OFFER TO BUY AVIGEN'S COMMON STOCK WILL BE MADE PURSUANT TO AN OFFER TO PURCHASE AND RELATED MATERIALS THAT BVF WILL FILE WITH THE SECURITIES AND EXCHANGE COMMISSION UPON THE COMMENCEMENT OF THE OFFER. STOCKHOLDERS SHOULD READ THESE MATERIALS CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING THE TERMS AND CONDITIONS OF THE OFFER. STOCKHOLDERS WILL BE ABLE TO OBTAIN THE OFFER TO PURCHASE AND RELATED MATERIALS WITH RESPECT TO THE TENDER OFFER WHEN THEY BECOME AVAILABLE FOR FREE AT THE SEC'S WEBSITE AT WWW.SEC.GOV OR FROM BVF BY CONTACTING MACKENZIE PARTNERS, INC. TOLL-FREE AT (800) 322-2885 OR COLLECT AT (212) 929-5500 OR VIA EMAIL AT TENDEROFFER@MACKENZIEPARTNERS.COM.

Any forward-looking statements contained in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently subject to a variety of risks and uncertainties that could cause actual results to differ materially from those projected. These risks and uncertainties include, among others: whether the conditions to the offer will be satisfied; the receipt of third party consents to the extent required for the acquisition, general economic factors, business and capital market conditions, general industry trends, changes in tax law require
'/>"/>

SOURCE Biotechnology Value Fund, L.P.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioSpace and the Massachusetts Biotechnology Council Inc. Launch 2009 Genetown™ Hotbed Campaign
2. Biotechnology Veteran Michael Webb Joins Boston-based Investment Bank as Senior Advisor
3. Biotechnology Value Fund, L.P. Calls Special Meeting of Avigen Stockholders To Remove Incumbent Directors and Elect Slate of Stockholder-Focused Nominees
4. Bolder BioTechnology Receives $1.9 Million NIH Grant to Continue Development of Long-Acting Growth Hormone Product
5. Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc.
6. Micromet Added to NASDAQ Biotechnology Index
7. Far From Beyond: A Glimpse into the World of Biotechnology and the Future of the Free World
8. North Carolinas Biotechnology Investment Tops Billion-Dollar Mark; Battelle Study Quantifies Economic Dividends and Jobs
9. Yongye Biotechnology Announces Record Third Quarter Results
10. World Market for Biotechnology Reagents to Reach $32.5 Billion by 2012, According to New Report by Global Industry Analysts, Inc.
11. Yongye Biotechnology to Present at Roth Capital China Comes to Vegas Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015  Novartis is ... study of CTL019, an investigational chimeric antigen receptor ... in the treatment of specific types of hard-to-treat ... by the University of Pennsylvania,s Perelman School of ... (r/r) diffuse large B-cell lymphoma (DLBCL) and follicular ...
(Date:6/1/2015)... IL (PRWEB) June 01, 2015 ... developing and manufacturing of chiral stationary phases (CSPs) ... options for its current and presenting solutions for ... to its portfolio. This valuable addition to its ... and effective advantage that can tackle projects for ...
(Date:6/1/2015)... 1, 2015  Boston-based Veritas Genetics is launching ... and bring personalized medicine and prevention to the ... their health. Beginning with its first product, a ... risk, Veritas Genetics is making its products affordable ... amount of genetic data which will be shared ...
(Date:6/1/2015)... MD (PRWEB) June 01, 2015 ... they have entered into a commercial collaboration agreement ... companies will combine their technologies and work together ... (MSC) regenerative technology. RoosterBio and Sistemic will collaborate ... technologies to build more precise and relevant characterization ...
Breaking Biology Technology:Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3Veritas Genetics To Advance Precision Medicine And Disease Prevention 2Veritas Genetics To Advance Precision Medicine And Disease Prevention 3Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 2Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 3Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 4
... Technologies LLC (Myriant), a privately-held, biotech developer and ... its Science Advisory Board and the appointment of ... will provide broad insight into all aspects of ... feedstocks into valuable chemicals. , (Logo: ...
... N.C., Oct. 21 Cornerstone Therapeutics Inc. (Nasdaq CM: ... and commercializing significant products primarily for the respiratory and ... conference call at 8:30 AM ET on Wednesday, November ... quarter ended September 30, 2009. Management will also ...
... ... business models capture investors, interest. , ... Miami, FL (PRWEB) October 21, 2009 -- iLife Americas, LLC, a ... in the U.S. to market its line of iLife wellness and therapeutic products. Officially ...
Cached Biology Technology:Myriant Technologies LLC Announces Appointment of Science Advisory Board Members 2Myriant Technologies LLC Announces Appointment of Science Advisory Board Members 3Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call 2Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call 3iLife Americas, LLC Enters U.S. Wellness and Therapeutic Markets 2
(Date:5/21/2015)... -- According to a new market ... Services), by Applications (Surveillance (Airborne, Maritime, Land), Threat ... & Defense & Commercial) - Global Forecast to ... expected to grow from $7252.0 Million in 2015 ... Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/19/2015)... YORK , May 19, 2015  Technology is ... both internally and in the cloud. Passwords and their ... use of OTP and standards-based specifications such as those ... the outmoded use of passwords presents for BYOD, COPE, ... a unified biometric identity protocol. In ...
(Date:5/11/2015)... 2015  Synaptics Incorporated (NASDAQ: SYNA ), ... announced the appointment of Wajid Ali ... reporting to Rick Bergman , President and ... Officer, Kathleen Bayless , who announced her ... Ali brings extensive financial management expertise to Synaptics, ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... and the Veterans Affairs Greater Los Angeles Healthcare System ... the cost-effectiveness of current modern drugs for treating hepatitis ... Published in the May 17 Annals of Internal Medicine, ... decisions. Researchers note that a degree of uncertainly exists ...
... known for a long time that only 2% -- 3% ... of our genomes -- often referred to as junk DNA ... RNA, reverse-transcribed into DNA, and then reinserted into a new ... class of these retroelements. Retroviruses can insinuate themselves into the ...
... Don't miss out the cool movies, link at the end ... Medicine researchers have found a way to exercise a little ... their wings, and fly on command by triggering genetic "remote ... central nervous systems, according to a new report in the ...
Cached Biology News:UCLA study assesses cost-effectiveness of Hepatitis B drugs 2UCLA study assesses cost-effectiveness of Hepatitis B drugs 3Chimp genome reveals a retroviral invasion 2Chimp genome reveals a retroviral invasion 3Remote control flies? Fly behavior controlled by laser light 2Remote control flies? Fly behavior controlled by laser light 3
...
5 minutes from gel band to purified DNA...
Sterile concentration of Dithiothreitol (DTT) solution in phosphate buffer (pH 7.0). Dilute contents in one vial (10- fold) to 100 ml. For use in liquefying sputum samples....
...
Biology Products: